DUBLIN--(BUSINESS WIRE)--The "Hospital Infection Therapeutics Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.
The report predicts the global hospital infection therapeutics market to grow with a CAGR of 4.61% over the forecast period of 2018-2024.
The global market size of hospital infection therapeutics market was worth around USD 3.13 billion and it is projected to reach to USD 4.32 billion in 2024.
The growth of the hospital infection therapeutics market is primarily due to increase number of patients admitted to hospitals, growing prevalence of several hospital infections and High number of pipeline drug molecules for specific treatment of healthcare associated infections.
Furthermore, lack of knowledge about the blood transfusion safety measures, understaffing, insufficient hospital equipment and poor infrastructure particularly seen in the developing and underdeveloped nations are some of factors responsible for spreading hospital infection which, in turn increases the hospital infection therapeutics market.
However, increase number of surveillance and infection control programs by government agencies, hospitals and other medical institutes may restrain the growth of this market.
Among the regions, the North America region accounted for the largest market share in 2017 followed by Europe. Major factors responsible for the leading position of the North American market includes rising number of multidrug- resistant microbial pathogens, increasing demand for advanced therapeutics and high prevalence of various hospital infections.
Besides this, rising geriatric population and high awareness level is contributing the growth of North American and European region respectively. Asia-Pacific is expected to grow at the highest CAGR on account of rising awareness, demand for new and improved hospital infection treatment drugs and increasing healthcare infrastructure are responsible for driving growth in this region over the forecast period.
The global hospital infection therapeutics market is segmented on the basis of by drug type and by major infections.
Global Hospital Infection Therapeutics Market by Drug Type
- Antibacterial Drugs
- Antiviral Drugs
- Antifungal Drugs
Global Hospital Infection Therapeutics Market by Major Infections
- Hospital Acquired Pneumonia
- Surgical Site Infections
- Urinary Tract Infection
- Gastrointestinal Disorders
- Bloodstream Infections
- Other Hospital Infections
- Bayer Ag
- Johnson & Johnson Services Inc.
- Actavis Plc
- Bristol Myers Squibb Company
- AstraZeneca Plc
- Pfizer Inc.
- Merck & Co, Inc.
- GlaxoSmithkline Plc
Cubist Pharmaceuticals, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/j7pb36/hospital?w=4